Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Skinmedica

<< Previous

Bullboard Posts

Next >>

Comment by tylerreddickon Oct 14, 2024 7:29pm

59 Views

Post# 36265667

RE:RE:Skinmedica

gr0und1ng wrote: ...the first milestone payment will be tied to the first commercial sale of each product in a certain geographic market. For example if they launch a skin lightener cream in the US that will be a milestone payment plus a royalty on the sale. If they launch in Canada at the same time, that's another milestone payment and the royalties also start at the point. If they launch a crme and a serum (for example) that's two separate milestone payments.

Well, Abbvie hasn't launched sweet fark all to date.
But it appears they aren't telling Howie anything, so who knows, we may get a big surprise one day (not holding my breath on that one)

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant